Search

everythinglearnresearchcommunity

for

Search:↓

Transplanting mice skin to humans is not feasible due to immune rejection, but some suggest genetic modification or immune suppression could make it possible. Xenograft hair transplants are discouraged.

The user is considering another hair transplant or scalp micropigmentation (SMP) for a congenital bald spot, but previous transplants were less effective due to scar tissue. Suggestions include using hair fibers, changing hairstyles, or doing nothing, as the spot is not very noticeable.

A 26-year-old male considering a hair transplant is using topical finasteride and minoxidil, planning to start feminizing hormone replacement therapy (HRT) with estrogen and spironolactone. Many suggest waiting to see the effects of HRT, which may significantly regrow hair, before deciding on a transplant, and recommend adding microneedling and possibly switching to oral treatments for better results.

Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to be overharvested without noticeable hair loss. The conversation questions if this method is practiced in clinics or if it's theoretical, and whether it relates to hair cloning or multiplication.

The conversation discusses using high molecular weight hyaluronic acid after microneedling to form a protective barrier, though it's considered expensive and offers marginal improvement. Users share experiences with different microneedling tools like derma rollers, dermastamps, and Dr. Pen, with some opting not to use any products on the scalp.

A user trying to avoid an expensive hair transplant, and the replies suggesting they wait two years on treatment before deciding if they need a transplant or not.

The user has been using HIMS chewable for two months to address lifelong thin hair. They are considering a hair transplant as a potential solution.

A 26-year-old male experienced hair thinning since age 18 and tried various treatments, including topical minoxidil, oral finasteride, and a hair transplant. He is currently using topical finasteride, minoxidil, tretinoin, hydrocortisone, and oral dutasteride, and is satisfied with the results 6.5 months post-transplant.

A 32-year-old male is considering options to soften a dense transplanted hairline after experiencing accelerated hair loss and intolerance to finasteride and dutasteride, while using minoxidil. He is exploring partial electrolysis or laser treatments to achieve a natural look with a short buzz cut, avoiding a second transplant or scalp micropigmentation.

User experienced severe allergic reactions and liver issues after a hair transplant, likely due to antibiotics and medications. Despite trying Minoxidil, the user faced further complications and is now seeking medical advice for potential future transplants.

The user underwent a hair transplant in Boston, initially dissatisfied with the results, but later achieved significant improvement in hair density and natural appearance after consulting a different surgeon. They used finasteride, minoxidil, and low-level laser therapy as part of their treatment.

A 24-year-old has been using Minoxidil and finasteride for 1.5 years with mild improvement but is being rejected for hair transplants due to age and diffuse thinning. They are seeking advice on what to do next.

Microneedling before a hair transplant may harden the scalp and affect blood circulation, potentially impacting graft growth. Some users report successful transplants after microneedling, while others advise caution and consulting with a surgeon.

The user is considering a hair transplant to increase hair density after using finasteride and minoxidil for two years. They prefer a natural hairline and are unsure if a transplant is suitable for overall thinning.

The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

A 35-year-old shared a 2-month update on their hair transplant of 3153 grafts, noting redness, itching, and some pimples, while using finasteride for over 12 years to maintain hair. Users discussed the effectiveness and timing of starting finasteride, with some suggesting consulting a doctor for young individuals considering the treatment.

A 35-year-old man shared his hair transplant experience in Tijuana, Mexico, choosing Artline for 5,000 grafts at a lower cost than U.S. clinics. He plans to use topical minoxidil and possibly microneedling for better results.

The user has severe diffuse thinning on the scalp and is using finasteride, topical minoxidil, dermarolling, tretinoin, and Nizoral without satisfactory results. They are considering a hair transplant but are concerned about the cost and the number of grafts needed.

A 30-year-old shared their successful hair restoration journey using liposomal topical finasteride and minoxidil, vitamins, and a second hair transplant in Greece, which significantly improved their hair density without side effects. The transplant cost $7500 and involved filling an old scar, with the user expressing gratitude for the life-changing results.

The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.

The user experienced significant hair regrowth using finasteride and minoxidil, leading to doubts about proceeding with a planned hair transplant. Many suggest postponing the transplant to save grafts for future needs, as the current results are impressive.

The conversation discusses concerns about microneedling potentially causing damage before a hair transplant, with users sharing their experiences and techniques. Specific treatments mentioned include using a dermapen at various depths and speeds, with some users advising against self-treatment.

User experienced hair loss after weight lifting, had a successful hair transplant, but later faced significant thinning. Current treatment includes finasteride, minoxidil, dermal rolling, and supplements.

Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.

A 35-year-old man had a hair transplant in 2019 but experienced further hair loss due to not using finasteride or minoxidil. Many suggest shaving his head or considering a hair system, as his donor area is depleted and further transplants may not be viable.

The user has been using 1MG finasteride, 5% minoxidil, LLLT, and derma stamping for a year to improve hair density for a potential transplant. They are considering switching to dutasteride and are unsure whether to proceed with a transplant now or wait for more growth.

Epibiotech will offer off-the-shelf allogeneic hair multiplication treatment in South Korea, using dermal papilla cells from donors to grow hair in balding areas. This method is cheaper and less invasive than traditional hair transplants.

The user is considering a second hair transplant or scalp micropigmentation to address thinning in the crown area and hide scars from a previous transplant. They have been using finasteride and minoxidil for three years but are concerned about the appearance of their donor area and the effectiveness of scalp micropigmentation.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.